10th International Symposium on Myelodysplastic Syndromes
Patrasso (Grecia), 6-9 maggio 2009

Webcast

7 maggio
Diagnosis and Prognosis I

• Myelodysplastic Syndromes: Update on Classification
  John M. Bennett, MD
• Real-time Prognostic Evaluation in MDS
  Luca Malcovati, MD
• Update of Cytogenetic Risk Features in MDS: Present State
  Detlef Haase, MD, PhD
• Update of Cytogenetic Rick Factors in MDS (Part II): A Strategy to Incorporate Fluorescence in situ Hybridization (FISH) and "FISH on a Chip" (aCGH) Results in Future Clinical Trials for the MDS
  Marilyn L. Slovak, PhD, FACMG

Diagnosis and Prognosis II

• Disruption of Precise Gene Product Expression in Myelodysplasia
  Michael R. Loken, PhD
• Identification of Prognostic Subgroups by Flow Cytometry in Myelodysplastic Syndromes
  Arjan A. van del Loosdrecht, MD, PhD
• Immunophenotypic Abnormalities Allow Distinction between Normal/Reactive and MDS Bone Marrow: How to Make it Easier?
  Alberto Orfao, Professor

• In Vitro Basis for Treatment with Hypomethylating Agents and HDAC Inhibitors: Can Epigentic Changes be Used to Monitoir Treatment?
  Steven D. Gore, MD
• Review of Trials with Azacytidine in Higher-risk MDS
  Pierre Fenaux, MD
• Decitabine in the Traetment of Higher-risk MDS
  David Steensma, MD, FACP
• Hypomethylating Agents in MDS Changing the Inevitable: The Value of Maintenance Therapy, Effects on Transfusions and Combination with other Agents
  Lewis Silverman, MD
• Hypomethylating Agents in Lower Risk MDS
  Valeria Santini, MD

9 maggio
Risk-adapted Treatment Strategies and Novel Therapies

• Low-risk MDS: Transfusion Therapy, Growth Factors and European View on Lenalidomide
  Eva-Hellström-Lindeberg, MD, PhD
• Management of Del (5q) MDS
  Aristoteles Giagoundis, MD
• Developmental Therapeutics for MDS
  Alan F. List, MD